Literature DB >> 29628270

Associations between adolescent cannabis use and brain structure in psychosis.

Hila Abush1, Subroto Ghose1, Erin A Van Enkevort1, Brett A Clementz2, Godfrey D Pearlson3, John A Sweeney1, Matcheri S Keshavan4, Carol A Tamminga1, Elena I Ivleva5.   

Abstract

Associations between cannabis use and psychotic disorders suggest that cannabis may be a contributory risk factor in the neurobiology of psychosis. In this study, we examined brain structure characteristics, total and regional gray matter density (GMD), using Voxel Based Morphometry, in psychotic individuals, stratified by history of cannabis use (total n = 109). We also contrasted GMD estimates in individual diagnostic groups (schizophrenia/bipolar I disorder) with and without history of adolescent cannabis use (ACU). Individuals with psychosis as a whole, both with and without history of ACU, had lower total and regional GMD, compared to healthy controls. ACU was associated with attenuated GMD reductions, compared to non-users, especially in the schizophrenia cases, who showed robust GMD reductions in fronto-temporal and parietal cortex, as well as subcortical regions. Notably, total and regional GMD estimates in individuals with psychosis and ACU were not different from controls with no ACU. These data indicate that the history of ACU in psychotic individuals is associated with attenuated GMD abnormalities. Future investigations targeting potential unique etiological and risk factors associated with psychosis in individuals with ACU may help in understanding of the neurobiology of psychotic disorders and novel treatment options for these individuals.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cannabis; Gray matter density; Psychotic bipolar disorder; Schizophrenia; Voxel Based Morphometry

Mesh:

Year:  2018        PMID: 29628270      PMCID: PMC5959798          DOI: 10.1016/j.pscychresns.2018.03.008

Source DB:  PubMed          Journal:  Psychiatry Res Neuroimaging        ISSN: 0925-4927            Impact factor:   2.376


  81 in total

Review 1.  The Impact of Exposure to Cannabinoids in Adolescence: Insights From Animal Models.

Authors:  Tiziana Rubino; Daniela Parolaro
Journal:  Biol Psychiatry       Date:  2015-08-07       Impact factor: 13.382

Review 2.  Cannabis use and transition to psychosis in individuals at ultra-high risk: review and meta-analysis.

Authors:  T Kraan; E Velthorst; L Koenders; K Zwaart; H K Ising; D van den Berg; L de Haan; M van der Gaag
Journal:  Psychol Med       Date:  2015-11-16       Impact factor: 7.723

3.  Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder.

Authors:  Glenn T Konopaske; Nicholas Lange; Joseph T Coyle; Francine M Benes
Journal:  JAMA Psychiatry       Date:  2014-12-01       Impact factor: 21.596

4.  A selective reduction in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia patients.

Authors:  Zhijun Zhang; Jing Sun; Gavin P Reynolds
Journal:  Chin Med J (Engl)       Date:  2002-06       Impact factor: 2.628

5.  Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP).

Authors:  Carol A Tamminga; Elena I Ivleva; Matcheri S Keshavan; Godfrey D Pearlson; Brett A Clementz; Bradley Witte; David W Morris; Jeffrey Bishop; Gunvant K Thaker; John A Sweeney
Journal:  Am J Psychiatry       Date:  2013-11       Impact factor: 18.112

Review 6.  Perineuronal nets and schizophrenia: the importance of neuronal coatings.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Neurosci Biobehav Rev       Date:  2014-04-04       Impact factor: 8.989

Review 7.  Association Between Cannabis and Psychosis: Epidemiologic Evidence.

Authors:  Suzanne H Gage; Matthew Hickman; Stanley Zammit
Journal:  Biol Psychiatry       Date:  2015-08-12       Impact factor: 13.382

8.  Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users.

Authors:  Marta Di Forti; Hannah Sallis; Fabio Allegri; Antonella Trotta; Laura Ferraro; Simona A Stilo; Arianna Marconi; Caterina La Cascia; Tiago Reis Marques; Carmine Pariante; Paola Dazzan; Valeria Mondelli; Alessandra Paparelli; Anna Kolliakou; Diana Prata; Fiona Gaughran; Anthony S David; Craig Morgan; Daniel Stahl; Mizanur Khondoker; James H MacCabe; Robin M Murray
Journal:  Schizophr Bull       Date:  2013-12-17       Impact factor: 9.306

9.  Cortical thickness in adolescent marijuana and alcohol users: A three-year prospective study from adolescence to young adulthood.

Authors:  Joanna Jacobus; Lindsay M Squeglia; Alejandro D Meruelo; Norma Castro; Ty Brumback; Jay N Giedd; Susan F Tapert
Journal:  Dev Cogn Neurosci       Date:  2015-04-27       Impact factor: 6.464

10.  Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies.

Authors:  P Fusar-Poli; R Smieskova; M J Kempton; B C Ho; N C Andreasen; S Borgwardt
Journal:  Neurosci Biobehav Rev       Date:  2013-06-14       Impact factor: 8.989

View more
  4 in total

Review 1.  Associations between cannabis use, cannabis use disorder, and mood disorders: longitudinal, genetic, and neurocognitive evidence.

Authors:  Lauren Kuhns; Emese Kroon; Karis Colyer-Patel; Janna Cousijn
Journal:  Psychopharmacology (Berl)       Date:  2021-11-06       Impact factor: 4.415

Review 2.  Adverse Effects of Recreational and Medical Cannabis.

Authors:  Ivan Urits; Karina Charipova; Kyle Gress; Nathan Li; Amnon A Berger; Elyse M Cornett; Hisham Kassem; Anh L Ngo; Alan D Kaye; Omar Viswanath
Journal:  Psychopharmacol Bull       Date:  2021-01-12

3.  The relationship between cannabis use and cognition in people with bipolar disorder: A systematic scoping review.

Authors:  T Jordan Walter; Nina Pocuca; Jared W Young; Mark A Geyer; Arpi Minassian; William Perry
Journal:  Psychiatry Res       Date:  2020-12-29       Impact factor: 3.222

4.  Adolescent Substance Abuse, Transgenerational Consequences and Epigenetics.

Authors:  Hamed Salmanzadeh; S Mohammad Ahmadi-Soleimani; Maryam Azadi; Robert F Halliwell; Hossein Azizi
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.